You can read the IBTA e-News December 2017 edition in full online here.
Some of the highlights from this month's include:
- A final analysis of a phase III trial (EF-14) in newly diagnosed adult glioblastoma has concluded Novocure’s Optune therapy in addition to maintenance temozolomide results in a significantly longer survival, compared to those who received temozolomide alone.
- The United States Food and Drug Administration (FDA) has granted full approval for bevacizumab (Avastin) in the treatment of adult patients with glioblastoma, whose tumour has progressed following prior therapy.
- Two drugs currently under investigation for glioblastoma and diffuse intrinsic pontine glioma (DIPG) may be rendered less effective due to the body’s own blood-brain barrier 'pumping' them out, according to findings from experiments published in the journal Investigational New Drugs.
- A fluorescent dye (5-ALA), which accumulates in brain tumour tissue and is visualised under special blue light, has been used alongside a newly designed 'spectroscopic' probe.
- In a study published in Cancer Cell, researchers have discovered that glioblastoma tumour cells possessing ‘Glut3 Addiction’ are highly sensitive to a class of drugs that target the αvβ3 molecule, such as cilengitide, meaning that they may be a potential treatment for a subset of brain tumour patients.
- The US Food and Drug Administration (FDA) has approved a study for INSIGHTEC’s ‘Exablate Neuro’ in patients with suspected glioblastoma. The technique involves an injection of a ‘microbubble’ solution into a patient’s bloodstream, followed by focused ultrasound waves to the brain, to cause temporary disruption (opening) of the blood brain barrier.
- On 7th December, the Scottish Parliament held a debate on brain tumour awareness in the country. The debate was the result of brain tumour fund-raiser Shona Richardson meeting her local MSP (Member of the Scottish Parliament), Alexander Stewart, to share with him the tragic story of her husband’s sudden death from an undiagnosed brain tumour.
- A new program developed by an Australian health care team called I-CoPE recommends that palliative and supportive care interventions for high-grade glioma patients should span their whole experience with the condition, rather than only from when they become symptomatic.
- NextSource Biotechnology has been accused of increasing the cost of lomustine capsules to "about US$768 per pill" (according to an article in the Wall Street Journal).
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.